The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Cystadenoma


High impact information on Cystadenoma

  • The renal cystadenomas develop from intercalated cells of the cortical collecting duct and uniformly express gelsolin at high levels, enabling detection of early neoplastic lesions [5].
  • Lack of telomerase expression in ovarian cystadenomas raises questions about the alleged immortality of these tumors because expression of this enzyme is thought to be essential for continuous growth in adult tumors [3].
  • Our findings provide cogent evidence that mutations of BRAF and KRAS occur in the epithelium of cystadenomas adjacent to SBTs and strongly suggest that they are very early events in tumorigenesis, preceding the development of SBT [6].
  • Here we show that a subset of cultured ovarian cystadenoma cells expressing SV40 large T-antigen, which allows bypassing of M1, develop a specific type of genomic instability, characterized by numerical (as opposed to structural) chromosomal alterations, that leads to non-telomere-based premature growth arrest/crisis [7].
  • Expression of COX-2 was detected in 42% of 86 ovarian carcinomas and in 37% of 19 low malignant potential tumors, but not in 12 cystadenomas or 2 normal ovaries [8].

Chemical compound and disease context of Cystadenoma

  • This report is concerned with identification of a new class of oligosaccharide ligand--sulfate-containing--for the human E-selectin molecule from among oligosaccharides on an ovarian cystadenoma glycoprotein [9].
  • In the ovary, corpora lutea were lacking while cysts were quite common in Tamoxifen-exposed mice at all doses; cystadenomas were seen in two mice [10].
  • Thirteen of 19 benign ovarian cystadenomas also expressed the epitope, but staining was weak and restricted to the luminal surface of the cell membrane [11].
  • A case of hepatobiliary cystadenoma with mesenchymal stroma is documented in which unequivocal immunostaining for progesterone receptors was observed in mesenchymal cells [12].
  • Hepatobiliary cystadenoma with mesenchymal stroma: expression of oestrogen receptors in formalin-fixed tissue [13].

Biological context of Cystadenoma


Anatomical context of Cystadenoma


Gene context of Cystadenoma


Analytical, diagnostic and therapeutic context of Cystadenoma


  1. Conservative management of the Zollinger-Ellison syndrome. Ectopic gastrin production by an ovarian cystadenoma. Long, T.T., Barton, T.K., Draffin, R., Reeves, W.J., McCarty, K.S. JAMA (1980) [Pubmed]
  2. Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadenomas. Zheng, J., Benedict, W.F., Xu, H.J., Hu, S.X., Kim, T.M., Velicescu, M., Wan, M., Cofer, K.F., Dubeau, L. J. Natl. Cancer Inst. (1995) [Pubmed]
  3. Telomerase activity in benign and malignant epithelial ovarian tumors. Wan, M., Li, W.Z., Duggan, B.D., Felix, J.C., Zhao, Y., Dubeau, L. J. Natl. Cancer Inst. (1997) [Pubmed]
  4. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Kwiatkowski, D.J., Zhang, H., Bandura, J.L., Heiberger, K.M., Glogauer, M., el-Hashemite, N., Onda, H. Hum. Mol. Genet. (2002) [Pubmed]
  5. Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. Onda, H., Lueck, A., Marks, P.W., Warren, H.B., Kwiatkowski, D.J. J. Clin. Invest. (1999) [Pubmed]
  6. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Ho, C.L., Kurman, R.J., Dehari, R., Wang, T.L., Shih, I.e.M. Cancer Res. (2004) [Pubmed]
  7. Aneuploidy and telomere attrition are independent determinants of crisis in SV40-transformed epithelial cells. Velicescu, M., Yu, J., Herbert, B.S., Shay, J.W., Granada, E., Dubeau, L. Cancer Res. (2003) [Pubmed]
  8. Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Denkert, C., Köbel, M., Pest, S., Koch, I., Berger, S., Schwabe, M., Siegert, A., Reles, A., Klosterhalfen, B., Hauptmann, S. Am. J. Pathol. (2002) [Pubmed]
  9. Novel sulfated ligands for the cell adhesion molecule E-selectin revealed by the neoglycolipid technology among O-linked oligosaccharides on an ovarian cystadenoma glycoprotein. Yuen, C.T., Lawson, A.M., Chai, W., Larkin, M., Stoll, M.S., Stuart, A.C., Sullivan, F.X., Ahern, T.J., Feizi, T. Biochemistry (1992) [Pubmed]
  10. Uterine carcinoma in mice treated neonatally with tamoxifen. Newbold, R.R., Jefferson, W.N., Padilla-Burgos, E., Bullock, B.C. Carcinogenesis (1997) [Pubmed]
  11. Expression of a polymorphic epithelial mucin antigen defined by the monoclonal antibody BC2 in ovarian carcinoma. Use of the BC2 antibody for the detection of micrometastases. McGuckin, M.A., Wright, G., Ward, B.G. Am. J. Clin. Pathol. (1991) [Pubmed]
  12. Immunohistochemical demonstration of progesterone receptor in hepatobiliary cystadenoma with mesenchymal stroma. Grayson, W., Teare, J., Myburgh, J.A., Paterson, A.C. Histopathology (1996) [Pubmed]
  13. Hepatobiliary cystadenoma with mesenchymal stroma: expression of oestrogen receptors in formalin-fixed tissue. Scott, F.R., More, L., Dhillon, A.P. Histopathology (1995) [Pubmed]
  14. Heterogeneous distribution of K-ras-mutated epithelia in mucinous ovarian tumors with special reference to histopathology. Mandai, M., Konishi, I., Kuroda, H., Komatsu, T., Yamamoto, S., Nanbu, K., Matsushita, K., Fukumoto, M., Yamabe, H., Mori, T. Hum. Pathol. (1998) [Pubmed]
  15. Differences in p16 gene methylation and expression in benign and malignant ovarian tumors. McCluskey, L.L., Chen, C., Delgadillo, E., Felix, J.C., Muderspach, L.I., Dubeau, L. Gynecol. Oncol. (1999) [Pubmed]
  16. Overexpression of latent transforming growth factor-beta 1 (TGF-beta 1) binding protein 1 (LTBP-1) in association with TGF-beta 1 in ovarian carcinoma. Higashi, T., Sasagawa, T., Inoue, M., Oka, R., Shuangying, L., Saijoh, K. Jpn. J. Cancer Res. (2001) [Pubmed]
  17. Telomerase activity is detected in pancreatic cancer but not in benign tumors. Hiyama, E., Kodama, T., Shinbara, K., Iwao, T., Itoh, M., Hiyama, K., Shay, J.W., Matsuura, Y., Yokoyama, T. Cancer Res. (1997) [Pubmed]
  18. Microcystic adenoma of the pancreas (glycogen-rich cystadenoma) with stromal amyloid deposits. Tripodi, S.A., Civitelli, S., Schürfeld, K., Cintorino, M. Histopathology (2000) [Pubmed]
  19. High concentrations of activin A in the peritoneal fluid of women with epithelial ovarian cancer. Cobellis, L., Reis, F.M., Luisi, S., Danero, S., Pirtoli, L., Scambia, G., Petraglia, F. J. Soc. Gynecol. Investig. (2004) [Pubmed]
  20. Mucinous biliary cystadenoma: a case report and review of the literature. Lind, D.S., Adolph, V., Parker, G.A. Journal of surgical oncology. (1992) [Pubmed]
  21. Intrahepatic biliary cystadenoma causing luminal common bile duct obstruction. Sutton, C.D., White, S.A., Berry, D.P., Dennison, A.R. Digestive surgery. (2000) [Pubmed]
  22. Promoter hypermethylation profile of ovarian epithelial neoplasms. Makarla, P.B., Saboorian, M.H., Ashfaq, R., Toyooka, K.O., Toyooka, S., Minna, J.D., Gazdar, A.F., Schorge, J.O. Clin. Cancer Res. (2005) [Pubmed]
  23. Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Rangel, L.B., Agarwal, R., D'Souza, T., Pizer, E.S., Alò, P.L., Lancaster, W.D., Gregoire, L., Schwartz, D.R., Cho, K.R., Morin, P.J. Clin. Cancer Res. (2003) [Pubmed]
  24. Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. Weichert, W., Denkert, C., Schmidt, M., Gekeler, V., Wolf, G., Köbel, M., Dietel, M., Hauptmann, S. Br. J. Cancer (2004) [Pubmed]
  25. Overexpression of p21WAF1/CIP1 and MDM2 characterizes serous borderline ovarian tumors. Palazzo, J.P., Monzon, F., Burke, M., Hyslop, T., Dunton, C., Barusevicius, A., Capuzzi, D., Kovatich, A.J. Hum. Pathol. (2000) [Pubmed]
  26. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Birner, P., Schindl, M., Obermair, A., Breitenecker, G., Oberhuber, G. Clin. Cancer Res. (2001) [Pubmed]
  27. Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival. Rosen, D.G., Wang, L., Jain, A.N., Lu, K.H., Luo, R.Z., Yu, Y., Liu, J., Bast, R.C. Clin. Cancer Res. (2004) [Pubmed]
  28. Secretory leukocyte protease inhibitor in ovarian endometriomas following GnRH agonist therapy. Suzumori, N., Sato, M., Ikuta, K., Suzumori, K. Obstetrics and gynecology. (2001) [Pubmed]
  29. Fluorescent neoglycolipids. Improved probes for oligosaccharide ligand discovery. Stoll, M.S., Feizi, T., Loveless, R.W., Chai, W., Lawson, A.M., Yuen, C.T. Eur. J. Biochem. (2000) [Pubmed]
WikiGenes - Universities